LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

Thomas Walter ,C Lombard Bohas,E Gaye,O Hentic Dhome,Mathieu Baconnier ,Léa Saban-Roche ,Vincent Hautefeuille ,Thierry Lecomte ,J.y Scoazec ,Thomas Aparicio ,C Pétorin ,Valérie Hervieu ,Patricia Niccoli ,Marine Perrier ,Sylvie Bin ,Rosine Guimbaud ,Christine Do Cao ,Julien Hadoux ,Marc Barritault ,Laura Gérard

doi:10.1016/j.annonc.2023.10.048

LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

Thomas Walter , C Lombard Bohas + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2023.10.048

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2023
Citations: 1

Affiliation: Hospices Civils de Lyon, Hôpital Edouard Herriot, Centre Oscar Lambret, Beaujon Hospital, Centre Hospitalier Annecy Genevois, Institute Cancer De La Loire Lucien Neuwirth, Centre Hospitalier Universitaire Amiens-Picardie, Centre Hospitalier Universitaire de Tours, Institut Gustave Roussy, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Clermont-Ferrand, Institute Paoli-Calmettes, University of Reims Champagne-Ardenne, Centre Hospitalier Universitaire de Reims, Hôpital Rangueil, Centre Hospitalier Universitaire de Toulouse, Centre Hospitalier Universitaire de Lille

#Oxaliplatin-based Chemotherapy #Neuroendocrine Tumours + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.